Figure 1

Cooperation between GNF-2 and suboptimal concentration of Imatinib and Dasatinib in inhibiting proliferation of Bcr-Abl transfected Ba/F3 cells. Ba/F3 cells, transfected with native p185 Bcr-Abl (A,C) and T315I mutated form (B,D) were treated with increasing GNF-2 concentrations and with Imatinib at 0.2 μM (A) and 1 μM (B), or with dasatinib at 2 nM (A) and 1 μM (B). In (C) and (D) percentage of viable Ba/F3 p185 Bcr-Abl (C) and Ba/F3 p185 Bcr-Abl T315I (D) cells treated with suboptimal concentration of Imatinib and Dasatinib for 72 h as described in Materials and Methods. IC₅₀ values +/− SD were calculated and blotted. Data are of representative experiment. Experiment was repeated 3 times with similar outcomes. P-values; * p<0.05, ** p<0.005.